Pascal COLOSETTI

2016-Today Research engineer within Inserm U1060-INRAe 1397-CarMeN (H. Vidal, Lyon, France): expertise in studying extracellular vesicles from different origins (eukaryotes and plants) Director of the European School for the Study of Extracellular Vesicles (ESSEV, @EV\_School\_ESSEV) 2012-2017 Member of the Inserm Scientific Council 2001-2016 Research engineer within Inserm U1065-C3M (P. Auberger, Nice, France): Extracellular vesicles (microvesicles and exosomes) in cancer, chemoresistance and inflammation 1997-2001 Research engineer within Inserm U442 (J.-P. Mauger, Orsay, France): InsP3R expression and regulation during cell polarization **Diplomas and qualifications** 2011 International Cancer Technology Transfer fellow at the Krefting Research Centre-Göteborg University, (Prof. J. Lötvall, Sweden) (UICC-ICRETT grant) 2008 Inter-university diploma (DIU) on acquired chromosomal pathologies (Bordeaux, Grenoble, Lille, Lyon, Marseille, Nice and Paris-Sud Universities) 2000 Transgenesis and homologous recombination diploma (Paris 6 University) 1994-1997 Postdoctoral fellow at the Laboratoire de Recherche en Oncologie of the Centre Alexis Vautrin (Nancy, France): Anticancer treatment resistance (Prof. J.-L. Merlin) 1991-1994 Postdoctoral fellow at the Ludwig Institute for Cancer Research (Uppsala, Sweden): TGF-beta activation and LTBP expression (Prof. C.-H. Heldin and Prof. K. Miyazono) 1991-1987 PhD in Biomedical Engineering at the Inserm U284 (Nancy University, France): TGF-beta 1 purification, a human platelet derived growth factor (C. Rivat and Prof. J.F. Stoltz) After completing my PhD on the TGF-beta 1 purification, a human platelet derived growth factor, at the Inserm U284 in Nancy, I was as a postdoctoral fellow at the Ludwig Institute for Cancer Research in Uppsala on TGF-beta activation and LTBP expression; followed by an other fellowship at the Laboratoire de Recherche en Oncologie (Centre Alexis Vautrin in Nancy) coordinating a cancer treatment resistance project. I then got a permanent position as research engineer at the Inserm U442 in Orsay to study the InsP3R expression during cell polarization. I next joined the Inserm U1065-C3M in Nice involved in cell death, differentiation, inflammation and cancer; last years, I developed skills in the characterization of extracellular vesicles (microvesicles, exosomes...) in cancer, chemoresistance and inflammation. I'm now part of the Inserm U1060-INRAe 1397-CarMeN in Lyon to study extracellular vesicles in metabolic disorders, founding and directing the European School for the Study of Extracellular Vesicles (ESSEV, @EV\_School\_ESSEV).

**Professional experience** 53 publications (December 15th, 2020) 2848 citations H-Index: 23 2016-Today Research engineer within Inserm U1060-INRAe 1397-CarMeN (H. Vidal, Lyon, France): expertise in studying extracellular vesicles from different origins (eukaryotes and plants) Director of the European School for the Study of Extracellular Vesicles (ESSEV, @EV\_School\_ESSEV) 2012-2017 Member of the Inserm Scientific Council 2001-2016 Research engineer within Inserm U1065-C3M (P. Auberger, Nice, France): Extracellular vesicles (microvesicles and exosomes) in cancer, chemoresistance and inflammation 1997-2001 Research engineer within Inserm U442 (J.-P. Mauger, Orsay, France): InsP3R expression and regulation during cell polarization **Diplomas and qualifications** 2011 International Cancer Technology Transfer fellow at the Krefting Research Centre-Göteborg University, (Prof. J. Lötvall, Sweden) (UICC-ICRETT grant) 2008 Inter-university diploma (DIU) on acquired chromosomal pathologies (Bordeaux, Grenoble, Lille, Lyon, Marseille, Nice and Paris-Sud Universities) 2000 Transgenesis and homologous recombination diploma (Paris 6 University) 1994-1997 Postdoctoral fellow at the Laboratoire de Recherche en Oncologie of the Centre Alexis Vautrin (Nancy, France): Anticancer treatment resistance (Prof. J.-L. Merlin) 1991-1994 Postdoctoral fellow at the Ludwig Institute for Cancer Research (Uppsala, Sweden): TGF-beta activation and LTBP expression (Prof. C.-H. Heldin and Prof. K. Miyazono) 1991-1987 PhD in Biomedical Engineering at the Inserm U284 (Nancy University, France): TGF-beta 1 purification, a human platelet derived growth factor (C. Rivat and Prof. J.F. Stoltz) After completing my PhD on the TGF-beta 1 purification, a human platelet derived growth factor, at the Inserm U284 in Nancy, I was as a postdoctoral fellow at the Ludwig Institute for Cancer Research in Uppsala on TGF-beta activation and LTBP expression; followed by an other fellowship at the Laboratoire de Recherche en Oncologie (Centre Alexis Vautrin in Nancy) coordinating a cancer treatment resistance project. I then got a permanent position as research engineer at the Inserm U442 in Orsay to study the InsP3R expression during cell polarization. I next joined the Inserm U1065-C3M in Nice involved in cell death, differentiation, inflammation and cancer; last years, I developed skills in the characterization of extracellular vesicles (microvesicles, exosomes...) in cancer, chemoresistance and inflammation. I'm now part of the Inserm U1060-INRAe 1397-CarMeN in Lyon to study extracellular vesicles in metabolic disorders, founding and directing the European School for the Study of Extracellular Vesicles (ESSEV, @EV\_School\_ESSEV).